Search Results

Results 1–20 of 39
Sort By: Relevance| Date| Title

1.
July 2008

Practice Bulletin Number 95, July 2008

Reaffirmed 2019

Members Only


2.
December 2012

Practice Bulletin Number 132, December 2012

(Replaces Practice Bulletin Number 118, January 2011). Reaffirmed 2019

Members Only


3.
December 2016

Members Only


4.
February 2008

Practice Bulletin Number 90, February 2008

(Reaffirmed 2019)

Members Only


Committee Opinion Number 532, August 2012

(Replaces No. 387, November 2007 and No. 322, November 2005) (Reaffirmed 2018)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall effectiveness, has reinforced its usefulness for short-term treatment of menopausal symptoms. Menopausal therapy has been provided not only by commercially available products but also by compounding, or creation of an individualized preparation in response to a health care provider’s prescription to create a medication tailored to the specialized needs of an individual patient. The Women’s Health...


Practice Bulletin Number 151, June 2015

(Replaces Practice Bulletin Number 20, September 2000). Reaffirmed 2019

Members Only


7.
November 2018

Practice Bulletin Number 200, November 2018

(Replaces Practice Bulletin Number 150, May 2015)

Early pregnancy loss, or loss of an intrauterine pregnancy within the first trimester, is encountered commonly in clinical practice. Obstetricians and gynecologists should understand the use of various diagnostic tools to differentiate between viable and nonviable pregnancies and offer the full range of therapeutic options to patients, including expectant, medical, and surgical management. The purpose of this Practice Bulletin is to review diagnostic approaches and describe options for the management of early pregnancy loss.


Committee Opinion Number 767, February 2019

(Replaces Committee Opinion Number 692, September 2017)

ABSTRACT: Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to...


Practice Bulletin Number 190, February 2018

(Replaces Practice Bulletin Number 180, July 2017) (Reaffirmed 2019)

Members Only


10.
September 2017

Members Only


Committee Opinion Number 776, April 2019

ABSTRACT: Because autoimmune conditions occur more often among women of childbearing age, continuation of these medications during pregnancy is often considered to optimize disease management in the woman and pregnancy outcomes, without placing the fetus at undue risk. Many commonly prescribed drugs can be used safely during pregnancy without risk of teratogenicity or pregnancy complications, whereas a few are strictly contraindicated. The decision to use any agent during pregnancy should be based on the clinical context, risks associated with individual medications, and gestational age. For ...


Members Only


13.
December 2016

Members Only


14.
August 2009

Practice Bulletin Number 107, August 2009

Replaces Practice Bulletin Number 10, November 1999; Committee Opinion Number 228, November 1999; Committee Opinion Number 248, December 2000; Committee Opinion Number 283, May 2003 (Reaffirmed 2019)

Members Only


Practice Bulletin Number 197, July 2018

(Replaces Practice Bulletin Number 138, September 2013)

Members Only


Committee Opinion Number 743, July 2018

ABSTRACT: Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia. The American College of Obstetricians and Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending daily low-dose aspirin beginning in the late first trimester for women with a history of early-onset preeclampsia and preterm delivery at less than 34 0/7 weeks of gestation, or for women with more than one prior pregnancy complicated by preeclampsia. The U.S. Preventive Services Task Force published a similar guideline, although the list of indications...


Committee Opinion Number 652, January 2016

(Replaces Committee Opinion Number 573, September 2013) (Reaffirmed 2018)

ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classification was changed from Category A to Category D, and the labeling was changed to include this new warning information. However, the U.S. Food and Drug Administration’s change in classification addresses an unindicated and nonstandard use of magnesium sulfate in obstetric care. The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine continue to support ...


Practice Bulletin Number 192, March 2018

(Replaces Practice Bulletin Number 75, August 2006) (Reaffirmed 2019)

Members Only


Practice Bulletin Number 82, June 2007

(Replaces Practice Bulletin Number 8, October 1999) (Reaffirmed 2018)

Members Only


Practice Bulletin Number 146, August 2014

(Reaffirmed 2019)

Members Only


Advertisement

American College of Obstetricians and Gynecologists
409 12th Street SW, Washington, DC  20024-2188
Mailing Address: PO Box 96920, Washington, DC 20024-9998